{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yamamoto Y"],"funding":["the Ministry of Education, Culture, Sports, Science and Technology and the Japan Society for Promotion of Science (KAKENHI)"],"pagination":["488"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12897004"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(3)"],"pubmed_abstract":["<h4>Background/objectives</h4>The role of preoperative neoadjuvant bevacizumab (neoBev) in newly diagnosed glioblastoma (GB) remains controversial. We evaluated its impact on perioperative and survival outcomes and explored imaging-based associations with prognosis.<h4>Methods</h4>We retrospectively analyzed 33 patients with newly diagnosed GB who received preoperative neoBev (10 mg/kg; surgery performed 21-30 days later). A matched control cohort of 33 patients treated with standard chemoradiotherapy was selected using propensity score matching. Changes in Karnofsky Performance Status (KPS), extent of resection, and volumetric alterations on gadolinium-enhanced T1-weighted MRI (T1Gd) and FLAIR were assessed. Progression-free survival (PFS) and overall survival (OS) were compared.<h4>Resul"],"journal":["Cancers"],"pubmed_title":["Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching."],"pmcid":["PMC12897004"],"funding_grant_id":["21K09161 and 25K12326"],"pubmed_authors":["Tamura R","Morimoto Y","Miyake K","Sasaki H","Yamamoto Y","Tanaka T","Takei J","Murayama Y","Tomoto K","Akasaki Y","Hasegawa Y","Teshigawara A"],"additional_accession":[]},"is_claimable":false,"name":"Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching.","description":"<h4>Background/objectives</h4>The role of preoperative neoadjuvant bevacizumab (neoBev) in newly diagnosed glioblastoma (GB) remains controversial. We evaluated its impact on perioperative and survival outcomes and explored imaging-based associations with prognosis.<h4>Methods</h4>We retrospectively analyzed 33 patients with newly diagnosed GB who received preoperative neoBev (10 mg/kg; surgery performed 21-30 days later). A matched control cohort of 33 patients treated with standard chemoradiotherapy was selected using propensity score matching. Changes in Karnofsky Performance Status (KPS), extent of resection, and volumetric alterations on gadolinium-enhanced T1-weighted MRI (T1Gd) and FLAIR were assessed. Progression-free survival (PFS) and overall survival (OS) were compared.<h4>Resul","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-08T03:11:35.582Z","creation":"2026-07-08T03:08:37.778Z"},"accession":"S-EPMC12897004","cross_references":{"pubmed":["41681960"],"doi":["10.3390/cancers18030488"]}}